Bank of Montreal Can Purchases 2,866 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of Montreal Can raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 188,157 shares of the biopharmaceutical company’s stock after acquiring an additional 2,866 shares during the quarter. Bank of Montreal Can’s holdings in Regeneron Pharmaceuticals were worth $196,189,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Quent Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 19 shares in the last quarter. CreativeOne Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $200,000. Gamco Investors INC. ET AL bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $230,000. Kennedy Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $5,210,000. Finally, Tidal Investments LLC increased its holdings in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 1.6 %

NASDAQ:REGN opened at $749.51 on Tuesday. The company has a market cap of $82.36 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $937.00 and a 200-day simple moving average of $1,025.99.

Wall Street Analyst Weigh In

REGN has been the subject of several research reports. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.48% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.